Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2019-11-04 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release issued by Strides Pharma Science Limited regarding the USFDA's announcement on laboratory testing and analysis of Ranitidine, specifically stating that Strides' Ranitidine Tablets are within acceptable NDMA limits. It is addressed to stock exchanges and includes contact information for investor relations and PR consultancy. The document does not contain financial statements, detailed financial analysis, or regulatory filings but is a public announcement of a regulatory update affecting the company's product. The length is under 5,000 characters and it is clearly a press release rather than a detailed report or filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance update.
2019-11-04 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is a letter dated October 25, 2019, addressed to stock exchanges, announcing the grant of stock options under the company's ESOP 2016 Plan. It details the number of options granted, exercise price, vesting period, and exercisable period. This is a notification about a share-based compensation event, specifically the granting of stock options to an employee. It is not a full financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The content fits the category of a Share Issue/Capital Change announcement, as it relates to the issuance of stock options which affect the company's capital structure.
2019-10-25 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a letter dated October 25, 2019, addressed to stock exchanges (BSE and NSE) announcing the allotment of shares under the company's ESOP (Employee Stock Option Plan) 2016. It specifies the number of shares allotted and confirms that these shares rank pari passu with existing shares. The content is a formal announcement of a share allotment event related to employee stock options, which is a capital change event. The document is short (1538 characters) and does not contain financial statements or detailed financial analysis, so it is not an Annual Report or Interim Report. It is not a report publication announcement or certification. The subject clearly relates to share allotment under ESOP, which falls under the category of Share Issue/Capital Change (SHA).
2019-10-25 English
Financial Result Updates
Regulatory Filings
2019-10-25 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short notice regarding the completion of dispatch of postal ballot notices to shareholders, referencing compliance with SEBI regulations. It includes no financial data, no detailed report, and no voting results. It is an announcement related to shareholder voting procedures, specifically about postal ballot and e-voting dispatch confirmation. Given the short length (1030 characters) and the nature of the content, it is not a full report or voting results announcement but rather a regulatory announcement related to shareholder voting process. Therefore, it fits best under Regulatory Filings (RNS) as a general compliance and disclosure notice.
2019-10-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release issued by Strides Pharma Science Limited regarding the announcement of test results by the Therapeutic Goods Administration (TGA) of Australia on Ranitidine batches. It provides updates on product safety, regulatory responses, and next steps but does not contain financial statements, detailed financial analysis, or regulatory filings. The document is a communication to the public and investors about a specific product safety issue and regulatory developments, typical of a press release. It is not an annual report, audit report, earnings release, or any other formal regulatory filing. Therefore, the most appropriate classification is a Regulatory Filing (RNS) as a general regulatory announcement and update that does not fit into more specific categories.
2019-10-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.